Have a specific question about your LBP project? Click below and let’s get started.
Description | Formulation | Abbrev. | Product # | ||||||
Protective Antigen from B. anthracis | |||||||||
Protective Antigen, native protein | Lyophilized in buffer | PA | 171 | ||||||
PA63 | Lyophilized in buffer | PA63 | 174 | ||||||
PA20 | Lyophilized in buffer | PA20 | 177 | ||||||
PA63 conjugated to FITC | Lyophilized in buffer | PA63-FITC | 175 | ||||||
Lethal Factor from B. anthracis | |||||||||
Lethal Factor, native sequence | Frozen Liquid | LF-A | 169L | ||||||
Lethal Factor, original product | Frozen Liquid | LF-HMA | 172L | ||||||
Lethal Factor, original product | Lyophilized in buffer | LF-HMA | 172 | ||||||
Lethal Factor, mutant E687C | Lyophilized in buffer | LF E687C | 176 | ||||||
LF Substrates | |||||||||
MAPKKide® Plus AMC | Lyophilized | MAPKKide® Plus | 532 | ||||||
MAPKKide® o-Abz/Dnp | Lyophilized | MAPKKide® 530 | 530 | ||||||
Unquenched Calibration peptide to use with #530, MAPKKide® o-Abz/Dnp | Lyophilized | 539 | |||||||
LF Antibodies | |||||||||
Anti-LF, affinity purified and biotinylated (chicken lgY) | In glycerol | Anti-LF Biotinylated | 768L | ||||||
Edema Factor from B. anthracis | |||||||||
Edema Factor, native sequence with an additional amino acid, histidine on the N-terminal | Lyophilized in buffer | EF | 178 | ||||||
EF mutant, S447N with reduced adenylate cyclase activity | Lyophilized in buffer | EF S447N | 173 |
$490.00
#171E (0.5 mg)
Anthrax Protective Antigen (PA), Recombinant from B. anthracis
Product # 171 is the entire 83 kDa native protein; This product contains the entire anthrax protective antigen 83 kDa native protein.$750.00
#172B (1 mg), #172L (1 mg),
$775.00 – $1,025.00
$980.00
#174 (0.5 mg)
Anthrax Protective Antigen, Activated (PA 63) from B. anthracis
Product # 174 is PA63, which has been created by enzymatic digestion and purified;$625.00
#175 (50 ug)
Anthrax PA 63 - FITC Conjugate
Product # 175 is purified PA63 conjugated to FITC for visualization.$475.00
$945.00
#177A (50 ug), #177B (.25mg),
Anthrax Protective Antigen Fragment (PA 20) from B. anthracis
Product # 177 is PA20, the approximately 20 kDA fragment cleaved from PA; and$355.00 – $675.00
#178A (0.1 mg)
$185.00
#530 (200 nmoles)
MAPKKide® Peptide Substrate (o-Abz/Dnp) for Anthrax Lethal Factor
Product # 530 is MAPKKide® utilizing the o-Abz/Dnp FRET pair. A calibration peptide, Product #539 is available for convenient use with the quenched substrate.$365.00
#531 (200 nmoles)
MAPKKide® Peptide Substrate (DABCYL/FITC) for Anthrax Lethal Factor
This product is discontinued.Product # 531 is MAPKKide® with the FRET pair DABCYL/FITC.#532 (100 nmoles)
MAPKKide® Plus (AMC) Specific Substrate for Anthrax Lethal Factor
Product # 532 is MAPKKide® Plus Specific Substrate for Anthrax Lethal Factor. This peptide is remarkable in its resistance to non-specific cleavage by enzymes which may be present in natural samples. MAPKKide® Plus carries the fluorophore 7-amido-4-methylcoumarin (AMC).$305.00
#539 (50 nmoles)
Unquenched Calibration Peptide for MAPKKide® 530 for Anthrax Lethal Factor
This product is discontinued.#768L (Liquid)
Anti-B. anthracis Lethal Factor (LF-A), lgY Antibody, Biotinylated
Product # 768L affinity purified and biotinylated Anti-Lethal Factor from B. anthracis (chicken lgY) works to detect the LF as described in the C of A.$415.00
#771B (1 mg)
Anti-Protective Antigen from B. anthracis (Goat)
This product is discontinued.Products # 771, purified IgG from goat, is directed to PA.Clinical And Vaccine Immunology
Peachman, KK;Li, Q;Matyas, GR;Shivachandra, SB;Lovchik, J;Lyons, RC;Alving, CR;Rao, VB;Rao, M;
Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis
Microbial Pathogenesis
Popova, TG;Millis, B;Bailey, C;Popov, SG;
Product: Anthrax Edema Factor (EF), Recombinant from B. anthracis
Glycoconjugate Journal
Tarasenko, O;Scott, A;Soderberg, L;Alusta, P;
Product: Anti-Protective Antigen from B. anthracis (Goat)
BMC Biotechnology
Andersen KK, Marcotte H, lvarez B, Boyaka PN, Hammarstrm L
Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis
Human Vaccine
Mett V, Chichester JA, Stewart ML, Musiychuk K, Bi H, Reifsnyder CJ, Hull AK, Albrecht MT, Goldman S, Baillie LW, Yusibov V
Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis
The Open Vaccine Journal
Li Q, Peachman KK, Sower L, Leppla SH, Shivachandra SB, Matyas GR, Peterson JW, Alving CR, Rao M, Rao VB
Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis
Infection and Immunity
Boyer AE, Quinn CP, Hoffmaster AR, Kozel TR, Saile E, Marston CK, Percival A, Plikaytis BD, Woolfitt AR, Gallegos M, Sabourin P, McWilliams LG, Pirkle JL, Barr JR
Product: Anthrax Lethal Factor (LF), Recombinant from B. anthracis
Antimicrogial Agents and Chemotherapy
Sharma S, Thomas D, Marlett J, Manchester M, Young JA
Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis
Molecular Therapy
Liu TH, Oscherwitz J, Schnepp B, Jacobs J, Yu F, Cease KB, Johnson PR
Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis
Plos One
Gupta PK, Moayeri M, Crown D, Fattah RJ, Leppla SH
Product: Anthrax Lethal Factor (LF), Recombinant from B. anthracis
Proceedings Of The National Academy Of Sciences Of The United States Of America
Bolcome, RE III; Sullivan, SE; Zeller, R; Barker, AP; Collier, RJ; Chan, J
Product: Anthrax Lethal Factor (LF), Recombinant from B. anthracis
Plos Pathogens
Manayani DJ, Thomas D, Dryden KA, Reddy V, Siladi ME, Marlett JM, Rainey GJ, Pique ME, Scobie HM, Yeager M, Young JA, Manchester M, Schneemann A
Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis
Bioorganic & Medicinal Chemistry
Karginov VA, Nestorovich EM, Schmidtmann F, Robinson TM, Yohannes A, Fahmi NE, Bezrukov SM, Hecht SM
Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis
BMC Pharmacology
Goldman ME, Cregar L, Nguyen D, Simo O, O'Malley S, Humphreys T
Product: Anthrax Lethal Factor (LF), Recombinant from B. anthracis
Clinical and Vaccine Immunology
Mabry R, Brasky K, Geiger R, Carrion R Jr, Hubbard GB, Leppla S, Patterson JL, Georgiou G, Iverson BL
Product: Anthrax Protective Antigen, Activated (PA 63) from B. anthracis
The Journal of Immunology
Fang H, Xu L, Chen TY, Cyr JM, Frucht DM
Product: Anthrax PA 63 – FITC Conjugate
Patent
Morrow P, Morrow J, Kang A, Wang F, Jiang I, Sawada R, Scholz W, Menos
Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis
Plos Pathogens
Alileche A, Serfass ER, Muehlbauer SM, Porcelli SA, Brojatsch J
Product: Anthrax Lethal Factor (LF), Recombinant from B. anthracis
List Labs POSTER - Presented at Bacillus Act 2005, September 25-29, 2005 in Sante Fe, New Mexico.
Shine, N., Le, C., Eaton, L., Crawford, K.
Product: Unquenched Calibration Peptide for MAPKKide® 530 for Anthrax Lethal Factor
The Journal of Infectious Diseases
Scobie HM, Thomas D, Marlett JM, Destito G, Wigelsworth DJ, Collier RJ, Young JA, Manchester M
Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis
Proceedings of the National Academy of Sciences of the United States of America
Forino M, Johnson S, Wong TY, Rozanov DV, Savinov AY, Li W, Fattorusso R, Becattini B, Orry AJ, Jung D, Abagyan RA, Smith JW, Alibek K, Liddington RC, Strongin AY, Pellecchia M
Product: MAPKKide® Peptide Substrate (o-Abz/Dnp) for Anthrax Lethal Factor
Occupational and Environmental Medicine
Biagini RE, Sammons DL, Smith JP, Page EH, Snawder JE, Striley CA, MacKenzie BA
Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis
The Journal of Biological Chemistry
Cordoba-Rodriguez R, Fang H, Lankford CS, Frucht DM
Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis
FMS Immunology and Medical Microbiology
Karginov VA, Robinson TM, Riemenschneider J, Golding B, Kennedy M, Shiloach J, Alibek K
Product: Anthrax Lethal Factor (LF), Recombinant from B. anthracis
The Journal of Biological Chemistry
Soelaiman S, Wei BQ, Bergson P, Lee YS, Shen Y, Mrksich M, Shoichet BK, Tang WJ
Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis
Proceedings of the National Academy of Sciences of the United States of America
Scobie HM, Rainey GJ, Bradley KA, Young JA
Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis
List Labs POSTER - Presented at the 5th International Conference on Anthrax, March 30, 2003 in Nice, France
Shine, N., Eaton, L., Crawford, K.
Product: MAPKKide® Peptide Substrate (DABCYL/FITC) for Anthrax Lethal Factor
April 14, 2022
By: List Labs
Anthrax toxin can enter living cells and the toxin enzymes, Lethal Factor (LF), and Edema Factor (EF) make known changes. Because of this activity, anthrax toxins are valuable tools to investigate cell processes. Some of the work currently accomplished with these toxins can be described by the following selected references: Work with anthrax toxins is […]
December 10, 2018
By: List Labs
A fast, sensitive, specific and accurate detection method to determine active infection Dr. Nancy Shine (408) 874-1305 NShine@ListLabs.com [Campbell, CA, 11/29/2018] • Method to detect Anthrax before it’s deadly • Anthrax is a problem for livestock • Test method is both specific and sensitive for Anthrax • List Labs is looking to partner on this […]
June 22, 2018
By: douano@listlabs.com
By: Rachel Berlin, Marketing Manager Microbiome research is uncovering the enormous potential for developing drugs, such a live biotherapeutic products, from the microbiome. This burgeoning field is the future of medicine. List Labs is excited and proud to support microbiome research by providing reagents to scientists studying the human microbiome. Below is a list of microbiome […]
February 20, 2018
By: douano@listlabs.com
By: Nancy Shine, PhD, Director of R&D, List Labs A fast, sensitive, specific and accurate detection method to determine active infection by Bacillus anthracis in plasma has been developed at List Biological Laboratories. Bacillus anthracis is regarded as a major biological warfare threat. The inhalation form of Bacillus anthracis infection can kill quickly. While antibiotic […]
January 23, 2018
By: douano@listlabs.com
By: Rachel Berlin, Marketing Manager List Labs is proud to be exhibiting at ASM Biothreats February 12-14th. The conference will be held in Baltimore, Maryland at the Hilton Hotel. Thought leaders in academia, industry and government will gather to present and discuss the latest developments in the emerging field of biothreats. This year’s conference has […]
September 11, 2017
By: douano@listlabs.com
Over 20 Scientific Posters Available on our website Scientific posters are a great way to visually display complex scientific issues. List Labs has a large list of scientific posters published on our website under the specific products they pertain to. We have been getting a lot of requests lately to compile a list of all […]
July 12, 2016
By: douano@listlabs.com
By: Nancy Shine, Ph.D., Director of Research & Development List Biological Laboratories, Inc. has designed a fluorescently labeled substrate for specific and quantitative detection of anthrax lethal factor in plasma. Bacillus anthracis is regarded as a major biological warfare threat. The inhalation form of Bacillus anthracis infection can kill quickly. While antibiotic treatment can clear […]
January 26, 2015
By: List Labs
By: Suzanne Canada, Ph.D. Tanager Medical Writing An exciting report was released in October about a new class of targeted anti-tumor drugs, in which genetically engineered stem cells were used to deliver cytotoxins to brain tumors.1 Brain cancers known as glioblastomas (GBM) are notoriously difficult to treat because the tumors often re-grow after surgery and because […]
January 5, 2015
By: List Labs
By: Suzanne Canada, Ph.D. Tanager Medical Writing Three anthrax toxin components—Protective antigen (PA), edema factor (EF) and lethal factor (LF) are available for research purposes from LIST Biological Laboratories, separately at a high level of purification. At least two out of three of these components are necessary to enter a mammalian cell and exert […]
October 21, 2014
By: List Labs
By: Suzanne Canada, Ph.D. Tanager Medical Writing Vaccines have been used to help control diseases for more than 200 years and are the common practice for children and adults. Childhood vaccination has substantially reduced the morbidity and mortality from infectious diseases in much of the developed world, and influenza vaccinations have reduced the impact […]
April 28, 2014
By: dpinkston@listlabs.com
What Are Toxin Neutralization Assays & How Do They Work? For clinical detection or vaccine testing, it is hard to beat a toxin neutralization assay. Toxin neutralization assays (TNA) assess the ability of antibodies to protect cells in culture from the cytotoxic affect of the specific toxins. Interestingly, these assays may be used for sensitive […]
Have a specific question about your LBP project? Click below and let’s get started.
List Labs
540 Division Street
Campbell, California
List Biotherapeutics
9800 Crosspoint BIvd Suite 2011
Indianapolis, IN 46256, USA